 DALLAS, March 18, 2021 GLOBE NEWSWIRE -- Instil Bio, Inc. Instil, a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer, today announced the pricing of its upsized initial public offering of 16,000,000 shares of common stock at a price to the public of 20.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Instil, are expected to be 320.0 million, excluding any exercise of the underwriters option to purchase additional shares. 